Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
2.

Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.

Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.

Breast Cancer Res Treat. 2014 Apr;144(2):249-61. doi: 10.1007/s10549-014-2867-0. Epub 2014 Feb 19.

3.

A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.

Lee JY, Park YJ, Oh N, Kwack KB, Park KS.

Oncotarget. 2017 Jun 27;8(26):42752-42760. doi: 10.18632/oncotarget.17459.

4.

The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).

De Lara S, Nyqvist J, Werner Rönnerman E, Helou K, Kenne Sarenmalm E, Einbeigi Z, Karlsson P, Parris TZ, Kovács A.

BMC Cancer. 2019 Feb 28;19(1):187. doi: 10.1186/s12885-019-5373-2.

5.

Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.

Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, Mo Q, Liao L, Xu J.

Oncogene. 2017 Feb 23;36(8):1157-1166. doi: 10.1038/onc.2016.286. Epub 2016 Aug 15.

6.

Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.

Fishwick C, Higgins J, Percival-Alwyn L, Hustler A, Pearson J, Bastkowski S, Moxon S, Swarbreck D, Greenman CD, Southgate J.

Cell Death Differ. 2017 May;24(5):809-818. doi: 10.1038/cdd.2017.10. Epub 2017 Mar 10.

7.

FOXA1 in breast cancer.

Nakshatri H, Badve S.

Expert Rev Mol Med. 2009 Mar 5;11:e8. doi: 10.1017/S1462399409001008. Review.

PMID:
19261198
8.

Illuminating MSK1's role in tumour dormancy.

Grzelak CA, Ghajar CM.

Nat Cell Biol. 2018 Feb;20(2):124-126. doi: 10.1038/s41556-018-0035-1. No abstract available.

PMID:
29371707
9.

High nuclear MSK1 is associated with longer survival in breast cancer patients.

Pu X, Storr SJ, Ahmad NS, Rakha EA, Green AR, Ellis IO, Martin SG.

J Cancer Res Clin Oncol. 2018 Mar;144(3):509-517. doi: 10.1007/s00432-018-2579-7. Epub 2018 Jan 11.

10.

A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions.

Brunner AL, Li J, Guo X, Sweeney RT, Varma S, Zhu SX, Li R, Tibshirani R, West RB.

Genome Biol. 2014 May 23;15(5):R71. doi: 10.1186/gb-2014-15-5-r71.

11.

Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression.

Chen F, Li A, Gao S, Hollern D, Williams M, Liu F, VanSickle EA, Andrechek E, Zhang C, Yang C, Luo R, Xiao H.

Cell Death Dis. 2014 May 22;5:e1242. doi: 10.1038/cddis.2014.224.

12.

Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.

Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, Tseng LM, Shyr YM.

J Transl Med. 2017 May 4;15(1):97. doi: 10.1186/s12967-017-1192-x.

13.

Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.

Reyes D, Ballaré C, Castellano G, Soronellas D, Bagó JR, Blanco J, Beato M.

Oncogene. 2014 Mar 20;33(12):1570-80. doi: 10.1038/onc.2013.95. Epub 2013 Apr 22.

PMID:
23604116
14.
15.

FOXA1 represses the molecular phenotype of basal breast cancer cells.

Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA.

Oncogene. 2013 Jan 31;32(5):554-63. doi: 10.1038/onc.2012.62. Epub 2012 Mar 5.

16.

PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.

Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS.

Cancer Cell. 2013 Jun 10;23(6):753-67. doi: 10.1016/j.ccr.2013.04.026.

17.

The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.

Wang C, Mayer JA, Mazumdar A, Brown PH.

Breast Cancer Res Treat. 2012 Jun;133(2):487-500. doi: 10.1007/s10549-011-1775-9. Epub 2011 Sep 24.

18.

Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade.

Kumar B, Prasad M, Bhat-Nakshatri P, Anjanappa M, Kalra M, Marino N, Storniolo AM, Rao X, Liu S, Wan J, Liu Y, Nakshatri H.

Cancer Res. 2018 Sep 1;78(17):5107-5123. doi: 10.1158/0008-5472.CAN-18-0509. Epub 2018 Jul 11.

19.

GATA3 expression in advanced breast cancer: prognostic value and organ-specific relapse.

McCleskey BC, Penedo TL, Zhang K, Hameed O, Siegal GP, Wei S.

Am J Clin Pathol. 2015 Nov;144(5):756-63. doi: 10.1309/AJCP5MMR1FJVVTPK.

PMID:
26486740
20.

Significance of PELP1 in ER-negative breast cancer metastasis.

Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK.

Mol Cancer Res. 2012 Jan;10(1):25-33. doi: 10.1158/1541-7786.MCR-11-0456. Epub 2011 Nov 15.

Supplemental Content

Support Center